Concordance of AI-Assisted and Hybrid AI-Assisted Cervical Imaging Systems with Visual Inspection with Acetic Acid for Cervical Precancer Screening in West Bandung, Indonesia

在印度尼西亚西万隆地区,人工智能辅助和混合人工智能辅助宫颈成像系统与醋酸目视检查在宫颈癌前筛查中的一致性研究

阅读:1

Abstract

BACKGROUND: Cervical cancer remains a major cause of morbidity and mortality among women, particularly in low- and middle-income countries (LMICs) where screening access is limited. Visual Inspection with Acetic Acid (VIA) is widely used but subject to inter-observer variability. Artificial intelligence (AI)-assisted cervical imaging may improve standardization; however, real-world community evidence is limited. OBJECTIVE: To evaluate the concordance of AI-assisted and hybrid AI-assisted cervical imaging systems (CIS) relative to VIA findings in a community-based cervical precancer screening program in West Bandung, Indonesia. METHODS: A cross-sectional study was conducted among 71 women to assess concordance and operational performance of two AI-based approaches: an AI-assisted CIS (Cerviray AI(®), AIDOT Inc., Seoul, South Korea) and a hybrid AI-assisted CIS incorporating expert review within a VIA-based workflow. RESULTS: The AI-assisted CIS showed sensitivity of 66.7% (95% CI 20.8-93.9) and specificity of 95.6% (95% CI 87.8-98.5), with PPV 40.0% and NPV 98.5%. The hybrid approach demonstrated similar sensitivity (66.7%; 95% CI 20.8-93.9) and slightly higher specificity (97.1%; 95% CI 89.9-99.2), with PPV 50.0% and NPV 98.5%. VIA positivity was low (4.2%; 8.5% using a composite definition), likely inflating specificity and NPV. All metrics were calculated against VIA rather than histopathology. Agreement with VIA was moderate (κ = 0.472 and κ = 0.550). CONCLUSION: AI-assisted and hybrid CIS showed moderate agreement with VIA. Interpretation is limited by small sample size, wide confidence intervals for sensitivity, low disease prevalence, and use of VIA as the reference standard. These preliminary findings suggest a potential supportive role for AI-assisted imaging in LMIC screening, warranting validation in larger studies using histopathologic reference standards.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。